FDA Approvals - VIVUS to Present at the Lazard Capital Markets Third Annual
VIVUS to Present at the Lazard Capital Markets Third Annual Life Sciences Conference (FinanzNachrichten)
MOUNTAIN VIEW, Calif., Nov. 20 /PRNewswire-FirstCall/ -- VIVUS, ( Nachrichten ) Inc. , a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity and sexual health, today announced that Timothy E. Morris, Vice President Finance and CFO, will present at the Lazard ( Nachrichten ) Capital Markets Third Annual Life Sciences Conference.
FDA ends ban on silicone-gel breast implants Two companies' products are safe but not without risk, the agency said in (The Philadelphia Inquirer)
The government ended a 14-year virtual ban on silicone-gel breast implants yesterday despite lingering questions, making the devices available to tens of thousands of women who have clamored for them.